<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01915134</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejaingCH-npc-03</org_study_id>
    <nct_id>NCT01915134</nct_id>
  </id_info>
  <brief_title>Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed this study to evaluate the efficiency and the acute toxicities of
      recombinant human endostatin (endostar) combined with chemotherapy in the metastatic
      nasopharyngeal carcinoma (NPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse
      reaction of recombinant human endostatin (endostar) combined with chemotherapy to the
      metastatic nasopharyngeal carcinoma (NPC).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress free survival(PFS)</measure>
    <time_frame>2years after the inception assignment</time_frame>
    <description>PFS means assignment to the date of any local or distant progress of the disease using Kaplan-Meier calculate the progress free survival rates,and find out is there significant difference between these two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>1 year ,2 years and 3 years after the inception of the assignment</time_frame>
    <description>the overall survival denote to assignment to date of death from any cause. Using Kaplan-Meier to calculate the 2-year ,3-year,5-year overall survival rate,and find is there any significant difference between these two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 3 years</time_frame>
    <description>observe and record the toxicity profile(including but not limit to mucositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edition) during the neoadjuvant chemotherapy ,chemoradiation and follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The quality of life assessment</measure>
    <time_frame>participants will be followed for the duration of hospital stay,an expected average of 100 days and every 6 months thereafter for 3 years</time_frame>
    <description>According to the most commonly used questionnaire EORTC QLQ C30 and H&amp;N35 35 for evaluation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>Effects of Chemotherapy</condition>
  <condition>Stage IVC Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>EGP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Endostatin plus gemcitabine and cisplatin</intervention_name>
    <description>target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.</description>
    <arm_group_label>EGP group</arm_group_label>
    <other_name>Experimental: EGP group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and cisplatin</intervention_name>
    <description>only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.</description>
    <arm_group_label>GP group</arm_group_label>
    <other_name>No Intervention: GP group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metastatic nasopharyngeal carcinoma 6 months after first treatment,never receive any
             anticancer treatment except local radiotherapy to the bone metastasis，at least one
             measurable metastatic lesions，ECOG PS 0-1，Electrocardiogram (ecg) no special
             abnormal，comply with the test requirements, cooperate with regular follow-up.

        Exclusion Criteria:

          -  To give local treatment,clinical severe infection(&gt;grade 2),with the central nervous
             system metastases,ECOG PS≥2,patients with pregnancy or breastfeeding,has a history of
             peripheral nerve disease,concomitant with other serious diseases,ever or concomitant
             with other serious diseases except for Cervical carcinoma in situ,cure of basal cell
             carcinoma,bladder surface tumor,any cancer 3 years after curation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhong Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital Hangzhou, Zhejiang, China 310022</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaozhong Chen</last_name>
    <phone>86-571-88122098</phone>
    <email>cxzfyun@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Li</last_name>
    <phone>86-571-88122091</phone>
    <email>libindoctor@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Li</last_name>
      <phone>86-571-88122091</phone>
      <email>libindoctor@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xinglai Feng</last_name>
      <phone>86-571-88122092</phone>
      <email>fengxinglai@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bin Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>Recombinant Human Endostatin</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>gemcitabine and cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

